Rapiscan

regadenoson

Opinion

On 13 December 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rapiscan. The marketing authorisation holder for this medicinal product is GE Healthcare AS.

The CHMP adopted a new indication as follows:

“measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated (see sections 4.2 and 5.1).”

For information, the full indications for Rapiscan will be as follows:1

“Rapiscan is a selective coronary vasodilator for use in adults as a pharmacological stress agent for:

  • radionuclide myocardial perfusion imaging (MPI) in adults patients unable to undergo adequate exercise stress.
  • the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated (see sections 4.2 and 5.1).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold, removed text as strikethrough

Key facts

Name
Rapiscan
Agency product number
EMEA/H/C/001176
International non-proprietary name (INN) or common name
  • regadenoson
Active substance
  • regadenoson
Therapeutic area
Myocardial Perfusion Imaging
Date opinion adopted
13/12/2018
Company name
GE Healthcare AS 
Status
Positive
Application type
Post-authorisation

How useful was this page?

Add your rating
Average
1 rating